Project Grant R03TR005344
Award Date 9/12/25
Completion Date 9/11/27
Dollars Obligated $163K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Texas, USA
Similar Awards
- This $112,230 federal Project Grant awarded by the National Cancer Institute (CFDA 93.398 - Cancer Research Manpower) to The University of Texas M.D. Anderson Cancer Center will support research to evaluate the potential of Type 1 conventional dendritic cell (CDC1) vaccination, alone and in combination with anti-CTLA4 immune checkpoint blockade, to induce antigen spread and generate diverse, effective CD8+ T cell responses against melanoma tumors. The project aims to study the ability of CDC1...
- This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $2,253,869 to Celdara Medical, LLC to develop CM-HZ01, a novel non-alpha-IL2 therapeutic for the treatment of metastatic melanoma. The funding supports advancing CM-HZ01 to the Investigational New Drug (IND) application stage, with the goal of providing a best-in-class immunotherapy for patients with limited effective treatment options for this deadly form of skin cancer. The project...
- This federal Project Grant award from the National Cancer Institute (CFDA 93.395 Cancer Treatment Research) provides $198,103 to New York University School of Medicine to investigate the role of the immune microenvironment in melanoma bone metastasis. The research aims to define the mechanisms by which melanoma cells colonize the skeletal system and modify the bone microenvironment, as well as explore the interplay between tumor, skeletal, and immune cells during melanoma bone metastasis. The...
- This Project Grant award from the National Cancer Institute (NCI), under the federal Cancer Biology Research program (CFDA 93.396), provides $442,236 to the University of Alabama at Birmingham (UAB) from January 1, 2025 through December 31, 2029. The funding supports research to uncover a novel melanoma metastasis pathway driven by the YTHDF1 RNA-binding protein, and to evaluate therapeutic targeting of the IMPDH1 and TRKB/BDNF pathways that mediate this process. The research utilizes...
- This federal Project Grant award of $1,348,314.00 was provided by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) to The University of Texas MD Anderson Cancer Center. The funding supports a research project titled "BUILDING T-CELL PRODUCTS IN NF1-ASSOCIATED MPNST THROUGH ANTIGEN DISCOVERY AND EPIGENOME TARGETING". The project aims to conduct advanced biomedical research to transform healthcare for military service members,...
- This Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) provides $217,863 to the University of Colorado-Denver to compare natural killer (NK) cell profiles within melanoma tumors and during pregnancy. The objectives are to: 1) identify biomarkers that can predict risk of disease progression and response to immune checkpoint blockade (ICB) therapy for melanoma patients, and 2) define new therapeutic targets to limit disease progression or improve...
- This federal Project Grant award from the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program provides $754,766.00 to The University of Texas M.D. Anderson Cancer Center to investigate the role of microbiota and microbial extracellular vesicles in metastatic dormancy in melanoma. The award period runs from November 1, 2024 to October 31, 2027. The University of Texas M.D. Anderson Cancer Center is a prominent academic medical center with extensive...
- This Project Grant award from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) provides $528,157 to The University of Texas MD Anderson Cancer Center to develop innovative AI-based methods for discovering and optimizing T cell receptors (TCRs) for use in T cell engager therapies and spatial TCR sequencing-based antigen discovery. Specifically, the project will use the researchers' existing "PMTNet-OMNI" deep learning...
- This $421,685 federal Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) supports research conducted by the University of California, San Francisco (UCSF) to investigate the "reactive" immune system in tumors and the tumor microenvironment. The study aims to discover discrete immune cell niches within the tumor that can enhance the effectiveness of cancer immunotherapies. Using innovative spatial transcriptomics, genetic tools, and cellular...
- The Project Grant award titled "TARGETING PRMT3-IGF2BP1 AXIS-MEDIATED EPITRANSCRIPTOMIC REPROGRAMMING AS A NOVEL THERAPEUTIC STRATEGY TO OVERCOME IMMUNOTHERAPY RESISTANCE IN CCRCC" was awarded by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420). The $1,144,500 award to the University of Texas MD Anderson Cancer Center will fund research from September 1, 2025 through August 31, 2028 focused on developing novel therapeutic strategies to...